Detalhe da pesquisa
1.
Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study.
Euro Surveill
; 29(15)2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38606569
2.
Antimicrobial Activity of Cefiderocol against the Carbapenemase-Producing Enterobacter cloacae Complex and Characterization of Reduced Susceptibility Associated with Metallo-ß-Lactamase VIM-1.
Antimicrob Agents Chemother
; 67(5): e0150522, 2023 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37195077
3.
Direct Detection of Carbapenemase-Producing Klebsiella pneumoniae by MALDI-TOF Analysis of Full Spectra Applying Machine Learning.
J Clin Microbiol
; 61(6): e0175122, 2023 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37199638
4.
Simultaneous and divergent evolution of resistance to cephalosporin/ß-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
J Antimicrob Chemother
; 78(5): 1195-1200, 2023 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36918743
5.
Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel ß-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing Enterobacterales.
Antimicrob Agents Chemother
; 66(2): e0167621, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34807754
6.
Selection of AmpC ß-Lactamase Variants and Metallo-ß-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Antimicrob Agents Chemother
; 66(2): e0206721, 2022 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34930034
7.
Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
J Antimicrob Chemother
; 77(10): 2809-2815, 2022 09 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35904000
8.
Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections.
J Antimicrob Chemother
; 76(1): 91-100, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33083833
9.
Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales.
J Antimicrob Chemother
; 76(6): 1498-1510, 2021 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33677560
10.
Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection.
J Antimicrob Chemother
; 75(11): 3209-3217, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32728723
11.
HIV antibodies level as a marker of HIV persistence: the role of hepatitis C virus coinfection.
Eur J Clin Microbiol Infect Dis
; 39(8): 1503-1512, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32232689
12.
New Carbapenemase Inhibitors: Clearing the Way for the ß-Lactams.
Int J Mol Sci
; 21(23)2020 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33291334
13.
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone.
Antimicrob Agents Chemother
; 63(10)2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31383659
14.
Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum ß-Lactamase-Producing Enterobacterales".
Antimicrob Agents Chemother
; 66(5): e0035322, 2022 05 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35471039
15.
Activity of cefiderocol and innovative ß-lactam/ß-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double ß-lactamases under high and low permeability conditions.
Int J Antimicrob Agents
; 63(5): 107150, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513748
16.
Pseudomonasaeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group.
Clin Microbiol Infect
; 30(4): 469-480, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38160753
17.
Activity of aztreonam in combination with novel ß-lactamase inhibitors against metallo-ß-lactamase-producing Enterobacterales from Spain.
Int J Antimicrob Agents
; 61(4): 106738, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36736925
18.
Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis.
Lancet Reg Health Eur
; 34: 100736, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37753216
19.
In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification.
Int J Antimicrob Agents
; 62(4): 106935, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37541530
20.
Interplay between OXA-10 ß-Lactamase Production and Low Outer-Membrane Permeability in Carbapenem Resistance in Enterobacterales.
Antibiotics (Basel)
; 12(6)2023 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37370318